Glioblastoma

You have access
Hypo-fractionated Radiotherapy (HF-RT) Versus Conventionally Fractionated Radiotherapy (CF-RT) for Glioblastoma
OKSANA ZEMSKOVA, EUGENE PEDACHENKO, NATHAN Y. YU and DIRK RADES

Anticancer Research July 2023, 43 (7) 3121-3128; DOI: https://doi.org/10.21873/anticanres.16484
Open Access
Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy
OKSANA ZEMSKOVA, NATHAN Y. YU, PETER TRILLENBERG, MATTEO M. BONSANTO, JAN LEPPERT and DIRK RADES

Anticancer Research June 2023, 43 (6) 2725-2732; DOI: https://doi.org/10.21873/anticanres.16439
You have access
Moderately Hypofractionated Radio(chemo)therapy With Simultaneous Integrated Boost for Recurrent, Previously Irradiated, High-grade Glioma
PASCAL GRAEN, HANS CHRISTIANSEN, MANOLIS POLEMIKOS, CONSTANTIN HEETFELD, FRIEDRICH FEUERHAKE, BETTINA WIESE and ROLAND MERTEN

Anticancer Research May 2023, 43 (5) 2155-2160; DOI: https://doi.org/10.21873/anticanres.16377
You have access
Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors
JI HYUN PARK, HYUN SEOK LEE, JIN WOO CHOI, SO DUG LIM, HYEON KANG KOH, KYUNG RAE CHO, JOON CHO, YOUNG-CHO KOH and SO YOUNG YOON

Anticancer Research December 2022, 42 (12) 6091-6098; DOI: https://doi.org/10.21873/anticanres.16121
You have access
Primary Central Nervous System Post–transplant Lymphoproliferative Disorder Misdiagnosed as Glioblastoma: A Case Report
HAKU TANAKA, RYOSUKE MATSUDA, MITSUTOSHI NAKAMURA, ICHIRO NAKAGAWA and HIROYUKI NAKASE

Anticancer Research August 2022, 42 (8) 3975-3979; DOI: https://doi.org/10.21873/anticanres.15893
You have access
Expression of ENO1 Is Up-regulated in Low-grade Glioma and Positively Correlated With Meningioma Grade
DANG THUY DIEM DINH, SASKIA KUHL, LUKAS GÖRTZ, ROLAND GOLDBRUNNER and MARCO TIMMER

Anticancer Research May 2022, 42 (5) 2319-2326; DOI: https://doi.org/10.21873/anticanres.15711
You have access
Early Metabolic Changes in 1H-MRSI Predictive for Survival in Patients With Newly Diagnosed High-grade Glioma
MICHAEL H. WANG, WILSON ROA, KEITH WACHOWICZ, ATIYAH YAHYA, ALBERT MURTHA, JOHN AMANIE, JONATHAN CHAINEY, HARVEY QUON, SUNITA GHOSH and SAMIR PATEL

Anticancer Research May 2022, 42 (5) 2665-2673; DOI: https://doi.org/10.21873/anticanres.15744
You have access
Association of MGMT Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type IDH Glioblastoma
MOONSIK KIM, JIHWAN YOO, JONG HEE CHANG and SE HOON KIM

Anticancer Research January 2022, 42 (1) 335-341; DOI: https://doi.org/10.21873/anticanres.15490
You have access
Pharmacological Strategy for Selective Targeting of Glioblastoma by Redox-active Combination Drug – Comparison With the Chemotherapeutic Standard-of-care Temozolomide
AKIRA SUMIYOSHI, SAYAKA SHIBATA, ZHIVKO ZHELEV, THOMAS MILLER, DESSISLAVA LAZAROVA, GENOVEVA ZLATEVA, ICHIO AOKI and RUMIANA BAKALOVA

Anticancer Research December 2021, 41 (12) 6067-6076; DOI: https://doi.org/10.21873/anticanres.15426
You have access
Large Animal Models of Glioma: Current Status and Future Prospects
WILLIAM H. HICKS, CYLAINA E. BIRD, MARK N. PERNIK, ALI S. HAIDER, AKSHARKUMAR DOBARIYA, KALIL G. ABDULLAH, SALAH G. AOUN, R. TIMOTHY BENTLEY, AARON A. COHEN-GADOL, ROBERT M. BACHOO, BRUCE E. MICKEY, JUAN M. PASCUAL and TAREK Y. EL AHMADIEH

Anticancer Research November 2021, 41 (11) 5343-5353; DOI: https://doi.org/10.21873/anticanres.15347

Main menu

User menu

Search

Glioblastoma

Pages